Psychostimulant use and clinical outcome of repetitive transcranial magnetic stimulation treatment of major depressive disorder
Sign Up to like & getrecommendations! Published in 2022 at "Depression and Anxiety"
DOI: 10.1002/da.23255
Abstract: Repetitive transcranial magnetic stimulation (rTMS) is an effective treatment for major depressive disorder (MDD). Psychostimulant medication use may be associated with improved rTMS outcomes, but a detailed understanding of these relationships is lacking. read more here.
Keywords: magnetic stimulation; treatment major; repetitive transcranial; transcranial magnetic ... See more keywords
Transcranial Magnetic Stimulation for the Treatment of Major Depression: A retrospective outcome study comparing the effectiveness of rTMS therapy provided 3 treatments per week versus 5 treatments per week in a private practice setting
Sign Up to like & getrecommendations! Published in 2020 at "Brain Stimulation"
DOI: 10.1016/j.brs.2020.06.060
Abstract: Background: We performed a retrospective chart review to analyze patient outcomes in the treatment of Major Depression (MD) comparing 3 treatments per week versus 5 treatments per week rTMS protocols to determine if treatment frequency… read more here.
Keywords: week; treatment major; per week; treatments per ... See more keywords
The relationship between positive affect and negative affect during treatment for major depressive disorder
Sign Up to like & getrecommendations! Published in 2018 at "Psychotherapy Research"
DOI: 10.1080/10503307.2017.1292066
Abstract: Abstract Objective: The present study examined the relationship between positive affect (PA) and negative affect (NA) along the course of combined cognitive behavior therapy and pharmacological treatment for major depressive disorder (MDD). Method: Participants were… read more here.
Keywords: positive affect; relationship positive; treatment; treatment major ... See more keywords
Vortioxetine: a novel antidepressant for the treatment of major depressive disorder
Sign Up to like & getrecommendations! Published in 2019 at "Expert Opinion on Drug Discovery"
DOI: 10.1080/17460441.2019.1546691
Abstract: ABSTRACT Introduction: Vortioxetine is a novel antidepressant drug approved for the treatment of major depressive disorder (MDD) in adults. It is formulated into tablets and has a dose range of 5–20 mg. The recommended starting… read more here.
Keywords: vortioxetine; depressive disorder; treatment major; major depressive ... See more keywords
OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females
Sign Up to like & getrecommendations! Published in 2019 at "International Clinical Psychopharmacology"
DOI: 10.1097/yic.0000000000000290
Abstract: Supplemental Digital Content is available in the text. read more here.
Keywords: depressive disorder; major depressive; onabotulinumtoxina treatment; phase randomized ... See more keywords